Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Table 3 Select ongoing trials using MRD as a primary endpoint

Trial number	Phase	Patient population	Intervention	Primary outcomes	MRD platform
NCT04168502	3	FLT3 wild type AML ≤ 60 years	Chemotherapy + GO induction and consolidation; Glasdegib as post-HSCT maintenance	MRD negativity, DFS	Not specified
NCT04093505	3	AML ≥ 60 years	Chemotherapy + GO in induction (dosed day 1 vs. days 1, 4, 7); Glasdegib (versus placebo) in consolidation and maintenance	MRD negativity	MFC
NCT04284787	2	AML > 60 years	Azacitidine + Venetoclax +/− Pembrolizumab	MRD negative CR	MFC
NCT04214249	2	FLT3 wild type	Cytarabine + Idarubicine +/− Pembrolizumab	MRD negative CR	MFC
NCT03150004	2	Relapsed/refractory or secondary AML	CLAG-M	MRD negative CR	Not specified
NCT03549351		Any enrolled in specified interventional prospective randomized trials	Observational study	Correlation between MRD and OS	MFC

Trials using MRD as an independent primary outcome, except those trials that specifically include patients in MRD-positive remission (as shown in Table 2). GO gemtuzumab oligomycin, HSCT hematopoietic stem cell transplant, MRD measurable residual disease, DFS disease-free survival, MFC multiparameter flow cytometry, MDS myelodysplastic syndrome, allo-NK cells allogeneic natural killer cells, UCB umbilical cord blood, IL-2 interleukin-2, RT-qPCR reverse transcription-quantitative polymerase chain reaction, G-CSF granulocyte colony stimulating factor, CR complete response, CLAG-M cladribine, cytarabine, granulocyte colony stimulating factor, mitoxantrone, OS overall survival, CR_MRD- complete response with no measurable residual disease, NRM non-relapse mortality, CRR complete response rate, DLI donor lymphocyte infusion, CLAM clofarabine, cytarabine, mitoxantrone

ISSN: 1756-8722